Cardiac Toxicity after Radiotherapy for Breast Cancer: Myths and Facts

Mirko Nitsche\textsuperscript{a, b}, René Pahl\textsuperscript{b}, Karen Huber\textsuperscript{b}, Kirsten Eilf\textsuperscript{b}, Juergen Dunst\textsuperscript{b}

\textsuperscript{a}Zentrum für Strahlentherapie und Radioonkologie, Bremen/Westerstede, Germany; \textsuperscript{b}Klinik für Strahlentherapie, Karl-Lennert-Krebszentrum, Universität Kiel, Germany

Keywords
Breast cancer · Cardiotoxicity · Radiotherapy

Summary
Radiotherapy is an important component in the multidisciplinary treatment of breast cancer. In recent years, the cardiac risks of radiation have been discussed several times. This problem has long been known and resolved from the radiotherapeutic point of view. The current data is briefly described here.

Introduction
It is well known since the first meta-analysis by Cuzick and colleagues [1] from the 1980s (incidentally one of the first meta-analyses in medicine at all) that postoperative radiation therapy in breast cancer may have adverse effects in long-term survivors. Even then, an increased mortality was observed in long-term survivors.

In studies that were started after 1982 [2], these adverse effects of radiotherapy have not been observed anymore (table 1). The positive effects of radiotherapy therefore came more into play. With increasing follow-up, the weight of these recent studies in the meta-analyses has grown. This is surely one of the reasons why the survival benefit of radiotherapy has become increasingly apparent [3, 4]. On the basis of Scandinavian studies and cancer registries, a higher rate of cardiac deaths could be identified as the cause for increased long-term mortality. This was significant only in patients with left-sided breast cancer. Therefore, the radiation exposure of the heart was suspected as the cause. Detailed studies primarily from Scandinavia were able to demonstrate a clear dose-response relationship. This dose effect was already detected in the 2005 meta-analysis of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) [3] (table 2). Since then, these consolidated findings have been consistently taken into account for modern radiotherapy treatment planning [5]. The analysis recently published in the \textit{New England Journal of Medicine} is merely an update of the above-cited data and confirms the facts known for years [6].

Cardiotoxicity of Radiotherapy

Pathophysiology and Epidemiology
Cardiotoxicity after radiation therapy is not new and was already described in detail in the 1970s; clinical research at that time focused on young patients with mantle irradiation for Hodgkin’s disease. This treatment technique delivered high radiation doses to large proportions of the heart. Generally, pericarditis was observed as acute and late toxicity at that time, as well as congestive heart failure, ischemic coronary artery disease, arrhythmia, or myocardial infarction [7–9]. The leading cause of non-cancer mortality among long-term survivors after radiotherapy for Hodgkin’s lymphoma was cardiovascular death [10]. It should be noted that radiation doses applied to the whole heart have been much higher than in the treatment of breast cancer, even in those times [11–13]. In Scandinavian breast cancer studies, mainly an increased incidence of ischemic events and unclear cardiac deaths was observed [2, 6].

The exact cause of cardiotoxicity after radiotherapy for breast cancer is not clear [14]. Based on the clinical data and animal experiments, various causes of radiogenic cardiac toxicity are discussed. Experimental evidence suggests indirect harmful effects of microvascular and macrovascular damage on the myocytes. It has been postulated that radiotherapy leads to an acute inflammation within the heart blood capillaries and to continuous inflammatory
Processes, resulting in endothelial cell proliferation and formation of fibrin thrombi with obstruction of the myocardial capillary lumen. Further on, this could lead to ischemia and myocardial cell death. Cardiac tissue is replaced by fibrotic tissue, as the myocytes have no ability to divide [15]. Subsidiary, radiation also induces an inflammatory process in the major arteries of the heart, leading to accelerated atherosclerosis. Endothelial cell damage and transmigration of monocytes into the intima lead to the ingestion of lipoproteins and the formation of fatty streaks [15]. Therefore, it is quite comprehensible that epidemiologic studies detected baseline cardiac risk factors as independent risk factor for cardiovascular disease after radiotherapy. Those risk factors are age, hypertension, diabetes mellitus, total cholesterol, family history of early myocardial infarction, and smoking [15]. In animal experiments, changes in the density of beta-receptors are observed at low doses of radiation to the heart. It has been suggested that the increased stimulation of the sympathetic nerve serves to compensate subclinical myocardial injury [16]. Perhaps, a combination of all factors described above plays a role. Several studies deal with the effect of dose on specific cardiac structures in patients undergoing radiotherapy. Lind et al. [17] evaluated post-radiation regional myocardial heart perfusion changes with single-photon emission tomography (SPECT) in 69 patients. They correlated left anterior descending artery (LAD) distribution SPECT changes with percent irradiated left ventricle (LV) volume and risk factors for coronary artery disease. Radiotherapy for left-sided breast cancer was associated with short-term SPECT defects in vascular distribution, corresponding to the radiation portals 6 months after radiotherapy. They did not find increases in SPECT defects in heart regions outside the tangential photon beams. Factors related to the extent of perfusion defects were the percent irradiated LV, hormonal treatment, and pre-radiotherapy hypercholesterolemia. None of the patients experienced clinically significant short-term cardiac events like myocardial infarction, but it clearly shows the impact of radiotherapy on microvascularization in the myocardium. There is currently no defined threshold dose for the LAD and the definition of the LAD as organ at risk is difficult in its reproducibility [18]. Pericardial effusion (PE) in the treatment of breast cancer is a very rare event. Wei et al. [19] reported about PE in patients treated for esophageal cancer. The greatest risk was shown for patients with an irradiated heart volume of more than 46% with 30 Gy, resulting in 73% PE. Those doses are by far not achieved in radiotherapy for breast cancer, so that the pericardium as organ at risk does not play a definite role in breast cancer radiotherapy. The same applies to the aortic bulb and the valvular plane. The incidence of valvular disease is only related to mediastinal radiation doses > 30 Gy and younger age at irradiation, which was shown for survivors of Hodgkin’s disease. After 20 years of follow-up, Machann et al. [20] performed cardiac magnetic resonance imaging in 36 patients and revealed a hemodynamically relevant valvular dysfunction in 13 patients and a perfusion deficit in 21 patients.

**Table 1. Increased cardiac mortality only in old studies**

<table>
<thead>
<tr>
<th>Patient enrolment, years</th>
<th>Increase in risk for cardiac death (hazard ratio) in follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Up to 10 years</td>
</tr>
<tr>
<td>1973–1982</td>
<td>1.19</td>
</tr>
<tr>
<td>1983–1992</td>
<td>0.99</td>
</tr>
<tr>
<td>1993–2002</td>
<td>0.97</td>
</tr>
<tr>
<td>2003–2008</td>
<td>1.00</td>
</tr>
</tbody>
</table>

Irradiated patients had a higher rate of cardiac deaths compared to the control group without irradiation. When listing the studies in chronological order, this was only significant in studies that recruited until 1982 (significant risks are highlighted in the table in italics). In studies with recruitment from 1983 to 1992, a very small, not more significant risk resulted after more than 15 years. In subsequent work, increased cardiac mortality was no longer observed (modified from [2]).

**Table 2. Data of the EBCTCG, evaluation 2005**

<table>
<thead>
<tr>
<th>Heart dose, range (mean)</th>
<th>Total number of patients</th>
<th>Cardiac events in irradiated patients</th>
<th>Cardiac events in non-irradiated patients</th>
<th>Hazard ratio for annual risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–5 Gy (3 Gy)</td>
<td>9,982</td>
<td>2.9%</td>
<td>2.4%</td>
<td>1.08 (n.s.)</td>
</tr>
<tr>
<td>5–15 Gy (9 Gy)</td>
<td>7,850</td>
<td>5.4%</td>
<td>3.8%</td>
<td>1.32</td>
</tr>
<tr>
<td>&gt; 15 Gy (17 Gy)</td>
<td>2,265</td>
<td>11.0%</td>
<td>6.4%</td>
<td>1.63</td>
</tr>
</tbody>
</table>

Irradiated patients had a higher rate of cardiac deaths. In the low-dose group, this effect was not significant. In the group with higher radiation doses, cardiac events even increased in the control group without irradiation. This can be explained mainly by the fact that high doses of radiation were used in the earliest studies with long follow-up and thus higher cardiac risk became apparent in non-irradiated patients in the control group. As a consequence of the data, one should have an average heart dose of less than 3–5 Gy in modern technology. Under these conditions, there is no significant cardiac risk [3]. n.s. = Not significant.
Discussion

The recently published analysis of Darby et al. [6] confirms well-known data on cardiac risks in ancient studies and has identified a dose-response relationship, but it gives no conclusive answer to the most important question of how best to protect the heart against radiation toxicity. The cardiac radiation doses in the meta-analysis are rough estimates of each individual patient because 3-dimensional treatment planning with calculation of cardiac doses (which is the contemporary standard) was not yet possible [21]. Furthermore, only mean heart doses were presented in the analyses. The authors of the New England Journal of Medicine article concluded that all exposure of the heart to radiation is associated with an increased risk. From the radiotherapeutic point of view, this conclusion is unsustainable after careful analysis of the presented data. It is most likely that there is a threshold dose, and probably a volume effect. Unfortunately, neither a critical volume nor a critical threshold dose can be exactly determined based on these historical studies. In studies with modern technology (as of 1990), no increased rate of cardiac risks was observed [2]. In recent prospective studies, in which the heart dose was calculated as part of the treatment planning, the mean heart doses are well below the dose of 3 Gy, which is the threshold dose for a significant cardiac effect recently reported by Darby et al. [6]. As evidence for this low cardiac stress, we can refer to our recent multicenter ARO-2010-01 study. An innovative fractionation schedule (hypo fractionation with integrated boost) was tested, and doses to organs at risk were routinely determined and documented during treatment planning. The mean heart dose was only $1.48 \pm 0.9$ Gy ($n = 151$) [22]. Analyzing the more common normofractionated standard adjuvant tangential radiotherapy in breast cancer, another one of our own recent treatment studies also proved low cardiac toxicity. We found a mean heart dose of 3.9 Gy (range 1.7–6.1 Gy, standard deviation (SD) 2.2 Gy), using a widespread modern computed tomography (CT)-based 3-dimensional radiotherapy planning [23]. The irradiation dose to the heart is low even when the planning target volume (PTV) is enlarged in comparison to routinely standard tangential radiotherapy, as demonstrated by the recently completed European Organisation for Research and Treatment of Cancer (EORTC) study 22922. The study showed an advantage of additional irradiation of the parasternal lymph nodes. No increased cardiac mortality was seen although, from experience, the highest cardiac doses result from the irradiation of the parasternal lymph nodes [24]. Even in the combination of radiation therapy and chemotherapy with cardiotoxic drugs (e.g. anthracyclines, trastuzumab), no increased risk due to radiotherapy was observed [25–27]. The cardiac risk of radiotherapy in breast cancer is certainly less than the risks of several drug therapies. However, up to now, it still remains unclear if late effects after combination of both therapies can become manifest in old age with decreasing compensation ability of the heart. Finally, this is not a specific radiotherapeutic problem [27].

New Techniques for Cardiac Protection

At present, the deep inspiration breath hold technique (DIBH) is increasingly used more or less routinely [28–30]. In deep inspiration, the heart sinks down and the distance to the chest wall increases. First dosimetric studies on individual patients showed a significant reduction in heart and lung dose (figs. 1 and 2). It has to be clarified whether the unique dosimetric advantage is clinically relevant or not, so that the use of this method is currently not mandatory. Irradiation in prone position is another promising treat-
ment option. Several publications are in favor of replacing the supine standard treatment by the prone position for whole-breast irradiation, especially in patients with large breasts [31–33]. Recently, Mulliez et al. [31] reported a phase III randomized trial in this context, in which skin desquamation, dermatitis and edema were significantly reduced. Moreover, also the dose to the ipsilateral lung and the left anterior descending coronary artery were significantly reduced. Comparing the prone and supine treatment positions in 400 patients, Formentieri et al. [33] evaluated the in-field volumes of the heart receiving the full dose as a surrogate for normal-tissue exposure. They described a considerable anatomical variability of the volume range, but were also able to show a significantly lower mean dose to the heart in the prone position. Another way to reduce heart toxicity in radiotherapy of breast cancer is the use of the evolving techniques in accelerated partial breast irradiation (APBI), which exclusively targets only the lumpectomy site plus some margin. The rationale for APBI is based on the fact that 75–85% of the local recurrences after breast cancer surgery occurred at or near the original lumpectomy site [34]. Current techniques in the delivery of APBI are intraoperative radiotherapy (IORT), multi-interstitial brachytherapy, intracavitary brachytherapy, and also external beam radiotherapy. The available data on APBI suggests acceptable local control and survival in selected patients with low-risk breast cancer. However, APBI is not applicable in patients with high-risk features as evidence from modern trials with long-term follow-up is still missing in this context [35]. There are also a rising number of patients undergoing oncoplastic surgery, for which the role of APBI is also not yet defined. Further on, the techniques of APBI are not widely available and only delivered in specialized radiooncology departments. The German S3 guidelines from 2012 [36] state that APBI as sole intra- or postoperative radiation treatment does not represent the standard of care at that time. Outside of clinical trials, APBI should only be delivered to patients for whom whole-breast radiotherapy is not applicable.

Conclusion for Daily Practice

A significant cardiotoxicity in modern adjuvant radiotherapy for breast cancer has not been observed with the currently used modern radiation techniques, neither in simple nor in complex planning target volumes. This relates also to the combination of irradiation with chemotherapy and immunotherapy. Radiotherapy is now safer than in the past, but a longer follow-up is needed in order to verify the exact late effects.

Disclosure Statement

All authors declare no conflict of interests.

References


